This study involves study participants who have been clinically diagnosed with parkinsonian
syndrome or who are at-risk for parkinsonian syndrome, have a family history of
parkinsonian syndrome or exposure to environmental toxins potentially associated with
parkinsonian syndrome. Participants will have brain imaging to assess dopamine transporter
density. The imaging data coupled with family history and environmental exposure data may
provide important information about potential risk factors for parkinsonian syndrome.
The brain imaging is conducted at the Institute for Neurodegenerative Disorders in New
Haven, Connecticut. The imaging procedure occurs over a two day period.
On the first day participants are injected with [123I]ß CIT, an investigational radioactive
material that localizes in the brain. Study participants will also have a thorough
neurologic examination and standard neuropsychological testing, including testing of memory,
concentration, abstraction and visual spatial functions.
Twenty-four hours later study participants return to the Institute for Neurodegenerative
Disorders where an investigational scanning procedure will be used to obtain SPECT (single
photon emission computed tomography) images of the brain.
Participants may be contacted to repeat these procedures every 12 to 18 months.
- 22 years or older
- A clinical diagnosis of Parkinson's disease (PD), positive family history of PD
and/or potential exposure to environmental toxins
- Normal screening laboratory studies
- Psychiatric disease other than history of depression
- Significant medical disease including abnormalities on screening